All In Biotech

Drug Trial Radar · NCT07329972

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 Tablet(s) in Healthy Participants

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Nov 21, 2025

Primary completion

Dec 14, 2025

Study completion Dec 14, 2025

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a phase 1, open-label, randomized, four-period crossover study to evaluate the effect of food and rabeprazole on the ZN-A-1041 tablet formulation in healthy male and female participants.

Conditions

  • Healthy Volunteers

Interventions

  • ZN-A-1041 Formulation 1Drug

    Participants will receive a single dose of ZN-A-1041 Formulation 1 on each specified treatment.

  • ZN-A-1041 Formulation 2Drug

    Participants will receive a single dose of ZN-A-1041 Formulation 2 on each specified treatment.

  • RabeprazoleDrug

    Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Concentration (Cmax)Time frame: Days 1 to 8, 11 to 14, and 17 to 20
  2. Area Under the Concentration-time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t)Time frame: Days 1 to 8, 11 to 14, and 17 to 20
  3. AUC Extrapolated to Infinity (AUC0-∞)Time frame: Days 1 to 8, 11 to 14, and 17 to 20
  4. Geometric Mean Ratio and Associated 90% Confidence Interval (CI) of Cmax, AUC0-t, and AUC0-∞Time frame: Days 1 to 8, 11 to 14, and 17 to 20

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Daytona Beach Clinical Rsch Unit

    Daytona Beach, Florida

  • Fortrea Clinical Research Unit - Dallas

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.